<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272790</url>
  </required_header>
  <id_info>
    <org_study_id>D6010C00004</org_study_id>
    <secondary_id>GYN 49</secondary_id>
    <nct_id>NCT02272790</nct_id>
  </id_info>
  <brief_title>Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</brief_title>
  <official_title>A Multicentre Phase II Study of Adavosertib Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, four-arm lead-in safety and efficacy study in which adavosertib will
      be combined in four separate treatment arms as follows: adavosertib plus gemcitabine (Arm A);
      adavosertib plus weekly paclitaxel (Arm B); adavosertib plus carboplatin (Arm C); and
      adavosertib plus PLD (Arm D). A subset of patients will be evaluated for the safety
      assessment of each treatment arm.

      The adavosertib plus paclitaxel arm (Arm B) will enrol approximately 30 additional patients
      at selected sites as part of a further efficacy evaluation based on emerging data that
      suggests clinical activity.

      In addition, the adavosertib plus carboplatin arm (Arm C) will enrol approximately 23
      patients overall at selected sites as part of a further efficacy evaluation based on emerging
      data that suggests clinical activity.

      To further optimise the dosing schedule of adavosertib in Arm C, a safety expansion arm
      (referred to as Arm C2) of approximately 12 additional patients will be enrolled at selected
      sites to explore emerging pre-clinical and clinical data that suggest that prolonged
      adavosertib exposure may increase the clinical activity.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 30, 2015</start_date>
  <completion_date type="Anticipated">March 15, 2021</completion_date>
  <primary_completion_date type="Actual">December 13, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
    <description>Objective response rate is defined as the proportion of patients achieving a complete or partial tumour response according to RECIST v1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
    <description>The Disease Control Rate is defined as the proportion of patients achieving a complete response (CR), partial response (PR), or stable disease (SD) according to RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Throughout the duration of the study, approximately 19 months.</time_frame>
    <description>Duration of Response (DoR) is defined as the time from first documented tumour response until the date of documented progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (Median, 80% CI)</measure>
    <time_frame>Throughout the Study, Approximately 4 years</time_frame>
    <description>Progression-free survival (PFS) was defined as the elapsed time from date of first dose of AZD1775 until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment.
Progression-free survival was derived based on scan/assessment dates, not visit dates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (Median, 95% CI)</measure>
    <time_frame>Throughout the Study, Approximately 4 years</time_frame>
    <description>Progression-free survival (PFS) was defined as the elapsed time from date of first dose of AZD1775 until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment.
Progression-free survival was derived based on scan/assessment dates, not visit dates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Median, 80% CI)</measure>
    <time_frame>Throughout the Study, Approximately 4 years</time_frame>
    <description>Overall survival (OS) was defined as the elapsed time from the date of first dose of AZD1775 until death due to any cause. Any patient not known to have died at the time of the analysis was censored based on the last recorded date on which the patient was known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Median, 95% CI)</measure>
    <time_frame>Throughout the Study, Approximately 4 years</time_frame>
    <description>Overall survival (OS) was defined as the elapsed time from the date of first dose of AZD1775 until death due to any cause. Any patient not known to have died at the time of the analysis was censored based on the last recorded date on which the patient was known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gynecologic Cancer Intergroup (GCIG) CA-125 Response</measure>
    <time_frame>Throughout the study, approximately 4 years</time_frame>
    <description>The GCIG CA-125 response is defined as the proportion of patients achieving a 50% reduction in CA-125 levels from baseline, if baseline level is â‰¥2 x the upper limit of normal (ULN) within 2 weeks prior to starting treatment. Response must be confirmed and maintained for at least 28 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) by Maximum CTCAE Grade.</measure>
    <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
    <description>The number of patients experiencing at least one treatment-related adverse event (TEAE) by maximum CTCAE grade.
Severity Grade 1 = Mild; Severity Grade 2 = Moderate; Severity Grade 3 = Severe; Severity Grade 4 = Life Threatening; Severity Grade 5 = Fatal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) Related to Adavosertib by Maximum CTCAE Grade</measure>
    <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
    <description>The number and proportion of patients experiencing at least one treatment-related adverse event (TEAE) related to adavosertib by maximum CTCAE grade
Severity Grade 1 = Mild; Severity Grade 2 = Moderate; Severity Grade 3 = Severe; Severity Grade 4 = Life Threatening; Severity Grade 5 = Fatal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) Related to Chemotherapy by Maximum CTCAE Grade</measure>
    <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
    <description>The number of patients experiencing at least one treatment-related adverse event (TEAE) related to chemotherapy by maximum CTCAE grade.
Severity Grade 1 = Mild; Severity Grade 2 = Moderate; Severity Grade 3 = Severe; Severity Grade 4 = Life Threatening; Severity Grade 5 = Fatal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
    <description>The number of patients experiencing at least one serious adverse event (SAE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events Leading to Death</measure>
    <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
    <description>The number of patients experiencing at least one serious adverse event (SAE) leading to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Adverse Events Related to Adavosertib Leading to Treatment Discontinuation</measure>
    <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
    <description>The number of patients experiencing at least one treatment-related adverse event related to adavosertib leading to treatment discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Adverse Events Related to Adavosertib Leading to Dose Reduction</measure>
    <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
    <description>The number of patients experiencing at least one treatment-related adverse event related to adavosertib leading to dose reduction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Adverse Events Related to Adavosertib Leading to Treatment Interruption</measure>
    <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
    <description>The number of patients experiencing at least one treatment-related adverse event related to adavosertib leading to treatment interruption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Adverse Events Related to Chemotherapy Leading to Treatment Discontinuation</measure>
    <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
    <description>The number of patients experiencing at least one treatment-related adverse event related to chemotherapy leading to treatment discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Adverse Events Related to Chemotherapy Leading to Dose Reduction</measure>
    <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
    <description>The number of patients experiencing at least one treatment-related adverse event related to chemotherapy leading to dose reduction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Adverse Events Related to Chemotherapy Leading to Treatment Interruption</measure>
    <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
    <description>The number of patients experiencing at least one treatment-related adverse event related to chemotherapy leading to treatment interruption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Dose Adavosertib Cmax</measure>
    <time_frame>Pre-dose, 0.5 hr, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr</time_frame>
    <description>Maximum plasma concentration of adavosertib after a single oral dose (Cycle 1 Day 1) in combination with IV infusion of commonly used chemotherapy agents, including gemcitabine, paclitaxel, and carboplatin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Dose Adavosertib Cmax</measure>
    <time_frame>Pre-dose, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr</time_frame>
    <description>Maximum plasma concentration of adavosertib after a multiple oral doses (Cycle 1 Day 3) in combination with IV infusion of 40 mg/mÂ² pegylated liposomal doxorubicin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Dose Adavosertib Tmax</measure>
    <time_frame>Pre-dose, 0.5 hr, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr</time_frame>
    <description>The time to reach maximum plasma concentration of adavosertib after a single oral dose (Cycle 1 Day 1) in combination with IV infusion of commonly used chemotherapy agents, including gemcitabine, paclitaxel, and carboplatin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Dose Adavosertib Tmax</measure>
    <time_frame>Pre-dose, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr</time_frame>
    <description>The time to reach maximum plasma concentration of adavosertib after multiple oral doses (Cycle 1 Day 3) in combination with IV infusion of 40 mg/mÂ² pegylated liposomal doxorubicin.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation</condition>
  <arm_group>
    <arm_group_label>Arm A (adavosertib + gemcitabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adavosertib (175 mg PO) will be taken on Days 1-2, 8-9, and 15-16. Gemcitabine 800 mg/mÂ² will be administered IV on days 1, 8, and 15 of each 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (adavosertib + paclitaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days weekly (Days 1-3, 8-10, and 15-17). Weekly paclitaxel 80 mg/mÂ² IV will be administered according to institutional standards on Day 1, 8, and 15 of each 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C/C2 (adavosertib + carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm C: Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days (Days 1-3). Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21-Day cycle.
Arm C2: Five doses of adavosertib (225 mg PO BID) 2.5 days per dosing week (QW), on Weeks 1 (D1-3), 2 (D8-10) and 3 (D15-17), or on Weeks 1 (D1-3) and 2 (D8-10) ( 2 weeks on followed by 1 week off.) Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (adavosertib + PLD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five doses of adavosertib (175 mg or 225 mg) will be taken in approximate 12 hour intervals over 2.5 days (Days 1, 2, and 3) of each 28-day cycle. PLD will administered IV on Day 1 of each cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adavosertib</intervention_name>
    <description>Adavosertib will be taken as oral capsules with water, approx. 2 hours before or 2 hours after food.</description>
    <arm_group_label>Arm A (adavosertib + gemcitabine)</arm_group_label>
    <arm_group_label>Arm B (adavosertib + paclitaxel)</arm_group_label>
    <arm_group_label>Arm C/C2 (adavosertib + carboplatin)</arm_group_label>
    <arm_group_label>Arm D (adavosertib + PLD)</arm_group_label>
    <other_name>MK1775</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel will be administered as a 1-hour IV infusion (Â± 10 minutes) at a dose of 80 mg/m2 according to institutional standards on Days 1, 8, and 15 of each 28 Day cycle.
Patients should be pre-medicated with corticosteroids, diphenhydramine and/or H2 antagonists according to institutional standards.</description>
    <arm_group_label>Arm B (adavosertib + paclitaxel)</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin, at a dose calculated to produce an AUC of 5 will be administered by intravenous infusion according to institutional standards on Day 1 of each 21 Day cycle. The carboplatin dose will be calculated using the Calvert Formula based on the patient's glomerular filtration rate (GFR) which is estimated by using the creatinine clearance.</description>
    <arm_group_label>Arm C/C2 (adavosertib + carboplatin)</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 800 mg/mÂ² will be administered IV on Days 1, 8, and 15 of each 28-Day cycle.</description>
    <arm_group_label>Arm A (adavosertib + gemcitabine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLD</intervention_name>
    <description>PLD (pegylated liposomal doxorubicin) 40 mg/mÂ² IV will be given on Day 1 of each 28-Day cycle.</description>
    <arm_group_label>Arm D (adavosertib + PLD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  Has read and understands the informed consent form (ICF) and has given written IC
             prior to any study specific procedures.

          -  Histologic or cytologic diagnosis of epithelial ovarian, fallopian tube, or primary
             peritoneal cancer.

          -  Progressed within 6 months of completing at least 4 cycles of a first-line
             platinum-containing regimen for Stage III/IV disease. Patients with refractory disease
             (progression during platinum-containing therapy) are ineligible.

          -  No more than 2-4 prior treatment regimens for Stage III/IV disease, defined as
             investigational, chemotherapy, hormonal, biologic, or targeted therapy.

          -  Prior doxorubicin (or other anthracycline) at a cumulative dose of â‰¤ 360 mg/mÂ² or
             cumulative epirubicin dose of â‰¤ 720 mg/mÂ² (calculated using doxorubicin equivalent
             doses: 1 mg of doxorubicin = 1 mg PLD = 0.3 mg mitoxantrone = 0.25 mg idarubicin).
             Subjects without any prior anthracycline exposure can also be included. Applies to Arm
             D only.

          -  At least 1 measurable lesion according to RECIST v1.1.

          -  Any prior palliative radiation therapy must be completed at least 7 days prior to
             start of study treatment and patients must have recovered from any acute adverse
             effects prior to start of study treatment.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 - 1.

          -  Baseline Laboratory Values:

               1. ANC â‰¥1500/Î¼L

               2. HgB â‰¥ 9 g/dL with no blood transfusions in the past 28 days

               3. Platelets â‰¥ 100,000/Î¼L

               4. ALT &amp; AST â‰¤3 x ULN or â‰¤5 x ULN if known hepatic metastases

               5. Serum bilirubin within normal limits (WNL) or â‰¤1.5 x the ULN in patients with
                  liver metastases; or total bilirubin â‰¤3.0 x ULN with direct bilirubin WNL in
                  patients with well documented Gilbert's Syndrome.

               6. Serum creatinine â‰¤1.5 x the ULN and a calculated creatinine clearance (CrCl) â‰¥45
                  mL/min by the Cockcroft-Gault method.

          -  Left ventricular ejection fraction (LVEF) WNL of the institution as determined by
             multiple uptake gated acquisition (MUGA) or echocardiography (ECHO) (applies to Arm D
             only).

          -  Female patients, â‰¥18, (not of childbearing potential and fertile female patients of
             childbearing potential) who agree to use adequate contraceptive measures from 2 weeks
             prior to the study and until 1 month after study treatment discontinuation, who are
             not breastfeeding, and who have a negative serum or urine pregnancy test within 72
             hours prior to start.

          -  Predicted life expectancy â‰¥ 12 weeks

        Exclusion

          -  Use of a study drug (approved or investigational drug therapy) â‰¤21 days or 5
             half-lives (whichever is shorter) prior to the first dose of study treatment. For
             study drugs for which 5 half-lives is â‰¤21 days, a minimum of 10 days between
             termination of the study drug and administration of study treatment is required.

          -  Major surgical procedures â‰¤ 28 days of beginning study, or minor surgical procedures â‰¤
             7 days. No waiting period following port-a-cath placement, or any other central venous
             access placement.

          -  Grade &gt;1 toxicity from prior therapy (except alopecia or anorexia).

          -  Known malignant CNS disease other than neurologically stable, treated brain
             metastases, defined as metastasis having no evidence of progression or haemorrhage
             after treatment for at least 2 weeks (including brain radiotherapy). Must be off any
             systemic corticosteroids for the treatment of brain metastases for at least 14 days
             prior to enrolment.

          -  Patient has had prescription or non-prescription drugs or other products (i.e.
             grapefruit juice) known to be sensitive CYP3A4 substrates or CYP3A4 substrates with a
             narrow therapeutic index, or to be moderate to strong inhibitors or inducers of CYP3A4
             which cannot be discontinued 2 weeks prior to Day 1 of dosing and withheld throughout
             the study until 2 weeks after last dose of study drug.

          -  Caution should be exercised when inhibitors or substrates of P-gP, substrates of
             CYP1A2 with a narrow therapeutic range, sensitive substrates of CYP2C19 or CYP2C19
             substrates with a narrow therapeutic range are administered with adavosertib.

          -  Herbal medications should be discontinued 7 days prior to the first dose of study
             treatment.

          -  Any of the following cardiac diseases currently or within the last 6 months as defined
             by New York Heart Association (NYHA) â‰¥ Class 2:

               1. Unstable angina pectoris

               2. Congestive heart failure

               3. Acute myocardial infarction

               4. Conduction abnormality not controlled with pacemaker or medication

               5. Significant ventricular or supraventricular arrhythmias (patients with chronic
                  rate controlled atrial fibrillation in the absence of other cardiac abnormalities
                  are eligible).

          -  Adavosertib should not be given to patients who have a history of Torsades de pointes
             unless all risk factors that contributed to Torsades have been corrected. Adavosertib
             has not been studied in patients with ventricular arrhythmias or recent myocardial
             infarction.

          -  Corrected QT interval (QTc) &gt;470 msec at study entry or congenital long QT syndrome.

          -  Pregnant or lactating.

          -  Serious active infection at the time of enrolment, or another serious underlying
             medical condition that would impair the patient's ability to receive study treatment.

          -  Presence of other active cancers, or history of treatment for invasive cancer within 3
             years. Patients with Stage I cancer who have received definitive local treatment
             within 3 years, and whom are considered unlikely to recur, are eligible. Patients with
             previously treated in-situ carcinoma (i.e., non-invasive) are eligible, as are
             patients with prior non-melanoma skin cancers.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Moore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stephenson Cancer Center, University of Oklahoma Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-6996</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D6010C00004&amp;amp;attachmentIdentifier=617d4afb-03ad-4dac-9100-8ce0250343b6&amp;amp;fileName=D6010C00004_Statistical_Analysis_Plan_v5.0_redact-_Final_pdfa.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D6010C00004&amp;amp;attachmentIdentifier=ed07c4a3-8013-4481-a040-47104f414937&amp;amp;fileName=d6010c00004-csp-amendment-10-redact-_Final_pdfa.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 14, 2014</study_first_submitted>
  <study_first_submitted_qc>October 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2014</study_first_posted>
  <results_first_submitted>November 4, 2019</results_first_submitted>
  <results_first_submitted_qc>November 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 22, 2019</results_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>MK-1775</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02272790/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02272790/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This multi-center study was conducted at 20 sites: 18 in the USA, 1 in Canada, and 1 in The Netherlands. Ninety-five (95) patients were enrolled; 94 patients received treatment. The first patient started treatment on 2 Feb 2015; the final patients were still receiving treatment and were censored at the time of database lock on 14 Dec 2018.</recruitment_details>
      <pre_assignment_details>One hundred twenty-six (126) patients consented and underwent screening; 94 patients passed screening, whereas 32 patients failed screening tests and were not eligible. The Full Analysis Set consists of 94 patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A</title>
          <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
        </group>
        <group group_id="P2">
          <title>Arm B</title>
          <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
        </group>
        <group group_id="P3">
          <title>Arm C</title>
          <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
        </group>
        <group group_id="P4">
          <title>Arm C2</title>
          <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
        </group>
        <group group_id="P5">
          <title>Arm D-175 mg</title>
          <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
        </group>
        <group group_id="P6">
          <title>Arm D-225 mg</title>
          <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A</title>
          <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
        </group>
        <group group_id="B2">
          <title>Arm B</title>
          <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
        </group>
        <group group_id="B3">
          <title>Arm C</title>
          <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
        </group>
        <group group_id="B4">
          <title>Arm C2</title>
          <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
        </group>
        <group group_id="B5">
          <title>Arm D-175 mg</title>
          <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
        </group>
        <group group_id="B6">
          <title>Arm D-225 mg</title>
          <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="9.75"/>
                    <measurement group_id="B2" value="60.9" spread="8.16"/>
                    <measurement group_id="B3" value="62.1" spread="11.29"/>
                    <measurement group_id="B4" value="60.3" spread="6.96"/>
                    <measurement group_id="B5" value="57.3" spread="14.58"/>
                    <measurement group_id="B6" value="61.0" spread="7.16"/>
                    <measurement group_id="B7" value="60.7" spread="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.0" lower_limit="46" upper_limit="72"/>
                    <measurement group_id="B2" value="60.0" lower_limit="45" upper_limit="76"/>
                    <measurement group_id="B3" value="62.0" lower_limit="34" upper_limit="85"/>
                    <measurement group_id="B4" value="58.5" lower_limit="52" upper_limit="76"/>
                    <measurement group_id="B5" value="58.5" lower_limit="40" upper_limit="72"/>
                    <measurement group_id="B6" value="60.5" lower_limit="54" upper_limit="70"/>
                    <measurement group_id="B7" value="60.0" lower_limit="34" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥ 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>ECOG Performance Status: 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory, able to carry out light or sedentary work; 2 = Ambulatory and capable of all self care but unable to carry out any work activities. Up and about &gt; 50% of waking hours; 3 = Capable of only limited self care, confined to bed or chair &gt; 50% of waking hours; 4 = Completely disabled, cannot carry on any self care. Totally confined to bed or chair; 5 = Dead.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>PS = 0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PS = 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PS = 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PS = 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PS = 4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from 1st positive biopsy for disease to consent for this study (mean)</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="11.83"/>
                    <measurement group_id="B2" value="70.9" spread="46.42"/>
                    <measurement group_id="B3" value="62.3" spread="24.68"/>
                    <measurement group_id="B4" value="86.1" spread="55.67"/>
                    <measurement group_id="B5" value="61.4" spread="23.88"/>
                    <measurement group_id="B6" value="65.8" spread="20.82"/>
                    <measurement group_id="B7" value="68.0" spread="38.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from 1st positive biopsy for disease to consent for this study (median)</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" lower_limit="35.9" upper_limit="77.1"/>
                    <measurement group_id="B2" value="54.9" lower_limit="31.4" upper_limit="250.4"/>
                    <measurement group_id="B3" value="54.1" lower_limit="30.0" upper_limit="113.6"/>
                    <measurement group_id="B4" value="74.9" lower_limit="25.1" upper_limit="241.0"/>
                    <measurement group_id="B5" value="62.9" lower_limit="30.6" upper_limit="87.4"/>
                    <measurement group_id="B6" value="71.1" lower_limit="41.1" upper_limit="90.0"/>
                    <measurement group_id="B7" value="54.9" lower_limit="25.1" upper_limit="250.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Local or Regional Recurrence</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from local/regional recurrence to consent for this study (mean)</title>
          <description>Sixty-seven (67) patients has a local or regional recurrence.</description>
          <population>Sixty-seven (67) patients has a local or regional recurrence.</population>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="17"/>
                    <count group_id="B4" value="9"/>
                    <count group_id="B5" value="4"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.2" spread="14.98"/>
                    <measurement group_id="B2" value="34.3" spread="51.20"/>
                    <measurement group_id="B3" value="20.6" spread="20.23"/>
                    <measurement group_id="B4" value="47.0" spread="57.13"/>
                    <measurement group_id="B5" value="39.3" spread="27.78"/>
                    <measurement group_id="B6" value="5.2" spread="3.61"/>
                    <measurement group_id="B7" value="28.6" spread="41.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from local/regional recurrence to consent for this study (median)</title>
          <description>Sixty-seven (67) patients has a local or regional recurrence.</description>
          <population>Sixty-seven (67) patients has a local or regional recurrence.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="17"/>
                    <count group_id="B4" value="9"/>
                    <count group_id="B5" value="4"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.1" lower_limit="3.0" upper_limit="38.9"/>
                    <measurement group_id="B2" value="18.6" lower_limit="0.6" upper_limit="200.4"/>
                    <measurement group_id="B3" value="16.6" lower_limit="1.6" upper_limit="70.6"/>
                    <measurement group_id="B4" value="15.4" lower_limit="0.9" upper_limit="177.9"/>
                    <measurement group_id="B5" value="37.7" lower_limit="7.6" upper_limit="74.3"/>
                    <measurement group_id="B6" value="5.6" lower_limit="0.4" upper_limit="10.0"/>
                    <measurement group_id="B7" value="13.0" lower_limit="0.4" upper_limit="200.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Distant Metastases</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Serous Epithelial Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Endometrioid Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clear Cell Epithelial Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Transitional Cell/Brenner Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Squamous Cell Epithelial Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Undifferentiated Epithelial Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mucinous Epithelial Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed Epithelial Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histological Grade</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>G1 - Well Differentiated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>G2 - Moderately Differentiated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>G3 - Poorly Differentiated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>G4 - Undifferentiated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>GX - Grade cannot be assessed or Not Applicable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage at Initial Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>IC</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IIC</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IIIA</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IIIB</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IIIC</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metastatic Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sites of Metastatic Disease</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distant Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local or Regional Lymph Nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin or Subcutaneous</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Systemic Therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from end of most recent prior systemic therapy to consent for this trial (mean)</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.0" spread="9.54"/>
                    <measurement group_id="B2" value="14.4" spread="15.45"/>
                    <measurement group_id="B3" value="10.5" spread="7.81"/>
                    <measurement group_id="B4" value="15.4" spread="15.12"/>
                    <measurement group_id="B5" value="12.9" spread="11.36"/>
                    <measurement group_id="B6" value="13.4" spread="12.08"/>
                    <measurement group_id="B7" value="13.1" spread="12.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from end of most recent prior systemic therapy to consent for this trial (median)</title>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" lower_limit="2" upper_limit="25"/>
                    <measurement group_id="B2" value="6.9" lower_limit="1" upper_limit="82"/>
                    <measurement group_id="B3" value="6.9" lower_limit="0" upper_limit="27"/>
                    <measurement group_id="B4" value="9.4" lower_limit="2" upper_limit="53"/>
                    <measurement group_id="B5" value="10.5" lower_limit="2" upper_limit="32"/>
                    <measurement group_id="B6" value="12.2" lower_limit="1" upper_limit="36"/>
                    <measurement group_id="B7" value="7.6" lower_limit="0" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of prior treatment regimens</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease setting for most recent prior regimen</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Neoadjuvant</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adjuvant</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease setting for most recent prior regimen</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Adj/Neoadj in Localized disease (Stage I or II)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adjuvant in advanced disease (Stage III or IV)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neoadjuvant in advanced disease (Stage III or IV)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Best overall response to most recent prior regimen</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Complete Response (CR)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response (PR)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-CR/Non-PD</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease (SD)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Applicable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reason most recent prior regimen ended</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Completed planned treatment</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Toxicity</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Radiotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (mean)</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.5" spread="21.56"/>
                    <measurement group_id="B2" value="73.2" spread="15.89"/>
                    <measurement group_id="B3" value="75.7" spread="19.25"/>
                    <measurement group_id="B4" value="70.6" spread="9.45"/>
                    <measurement group_id="B5" value="70.2" spread="14.11"/>
                    <measurement group_id="B6" value="65.7" spread="8.61"/>
                    <measurement group_id="B7" value="72.8" spread="16.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (median)</title>
          <units>Kilograms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.6" lower_limit="47.6" upper_limit="124.1"/>
                    <measurement group_id="B2" value="69.6" lower_limit="47.4" upper_limit="117.6"/>
                    <measurement group_id="B3" value="71.5" lower_limit="44.8" upper_limit="114.0"/>
                    <measurement group_id="B4" value="67.7" lower_limit="56.9" upper_limit="85.1"/>
                    <measurement group_id="B5" value="68.2" lower_limit="56.2" upper_limit="95.1"/>
                    <measurement group_id="B6" value="67.8" lower_limit="51.1" upper_limit="74.4"/>
                    <measurement group_id="B7" value="69.7" lower_limit="44.8" upper_limit="124.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure (mean)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130.0" spread="15.23"/>
                    <measurement group_id="B2" value="125.2" spread="13.37"/>
                    <measurement group_id="B3" value="127.7" spread="10.65"/>
                    <measurement group_id="B4" value="122.3" spread="6.40"/>
                    <measurement group_id="B5" value="125.2" spread="17.22"/>
                    <measurement group_id="B6" value="127.5" spread="9.35"/>
                    <measurement group_id="B7" value="126.1" spread="12.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure (median)</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130.0" lower_limit="109.0" upper_limit="153.0"/>
                    <measurement group_id="B2" value="126.5" lower_limit="100.0" upper_limit="159.0"/>
                    <measurement group_id="B3" value="128.0" lower_limit="110.0" upper_limit="153.0"/>
                    <measurement group_id="B4" value="121.0" lower_limit="115.0" upper_limit="137.0"/>
                    <measurement group_id="B5" value="120.0" lower_limit="112.0" upper_limit="159.0"/>
                    <measurement group_id="B6" value="126.5" lower_limit="113.0" upper_limit="142.0"/>
                    <measurement group_id="B7" value="126.0" lower_limit="100.0" upper_limit="159.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure (mean)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.2" spread="10.96"/>
                    <measurement group_id="B2" value="76.7" spread="7.74"/>
                    <measurement group_id="B3" value="74.8" spread="8.03"/>
                    <measurement group_id="B4" value="74.4" spread="8.26"/>
                    <measurement group_id="B5" value="73.0" spread="6.66"/>
                    <measurement group_id="B6" value="78.7" spread="6.02"/>
                    <measurement group_id="B7" value="75.8" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure (median)</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.0" lower_limit="62.0" upper_limit="90.0"/>
                    <measurement group_id="B2" value="78.0" lower_limit="59.0" upper_limit="93.0"/>
                    <measurement group_id="B3" value="75.0" lower_limit="61.0" upper_limit="95.0"/>
                    <measurement group_id="B4" value="73.5" lower_limit="62.0" upper_limit="87.0"/>
                    <measurement group_id="B5" value="74.0" lower_limit="63.0" upper_limit="83.0"/>
                    <measurement group_id="B6" value="77.5" lower_limit="73.0" upper_limit="89.0"/>
                    <measurement group_id="B7" value="76.0" lower_limit="59.0" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area (mean)</title>
          <units>mÂ²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="0.25"/>
                    <measurement group_id="B2" value="1.8" spread="0.19"/>
                    <measurement group_id="B3" value="1.8" spread="0.22"/>
                    <measurement group_id="B4" value="1.8" spread="0.13"/>
                    <measurement group_id="B5" value="1.8" spread="0.18"/>
                    <measurement group_id="B6" value="1.7" spread="0.10"/>
                    <measurement group_id="B7" value="1.8" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area (median)</title>
          <units>mÂ²</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" lower_limit="1.5" upper_limit="2.3"/>
                    <measurement group_id="B2" value="1.8" lower_limit="1.4" upper_limit="2.3"/>
                    <measurement group_id="B3" value="1.8" lower_limit="1.4" upper_limit="2.3"/>
                    <measurement group_id="B4" value="1.7" lower_limit="1.6" upper_limit="2.0"/>
                    <measurement group_id="B5" value="1.7" lower_limit="1.6" upper_limit="2.1"/>
                    <measurement group_id="B6" value="1.7" lower_limit="1.5" upper_limit="1.8"/>
                    <measurement group_id="B7" value="1.7" lower_limit="1.4" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>Objective response rate is defined as the proportion of patients achieving a complete or partial tumour response according to RECIST v1.1 criteria.</description>
        <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>Objective response rate is defined as the proportion of patients achieving a complete or partial tumour response according to RECIST v1.1 criteria.</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR)</title>
        <description>The Disease Control Rate is defined as the proportion of patients achieving a complete response (CR), partial response (PR), or stable disease (SD) according to RECIST v1.1 criteria.</description>
        <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR)</title>
          <description>The Disease Control Rate is defined as the proportion of patients achieving a complete response (CR), partial response (PR), or stable disease (SD) according to RECIST v1.1 criteria.</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR)</title>
        <description>Duration of Response (DoR) is defined as the time from first documented tumour response until the date of documented progression or death from any cause.</description>
        <time_frame>Throughout the duration of the study, approximately 19 months.</time_frame>
        <population>Duration of Response (DoR) was calculated for all responders (N = 30)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR)</title>
          <description>Duration of Response (DoR) is defined as the time from first documented tumour response until the date of documented progression or death from any cause.</description>
          <population>Duration of Response (DoR) was calculated for all responders (N = 30)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="0" upper_limit="NA">non calculable</measurement>
                    <measurement group_id="O2" value="12.0" lower_limit="3.7" upper_limit="NA">non calculable</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">non calculable</measurement>
                    <measurement group_id="O4" value="10.4" lower_limit="5.8" upper_limit="NA">non calculable</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">non calculable</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">non calculable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (Median, 80% CI)</title>
        <description>Progression-free survival (PFS) was defined as the elapsed time from date of first dose of AZD1775 until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment.
Progression-free survival was derived based on scan/assessment dates, not visit dates.</description>
        <time_frame>Throughout the Study, Approximately 4 years</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (Median, 80% CI)</title>
          <description>Progression-free survival (PFS) was defined as the elapsed time from date of first dose of AZD1775 until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment.
Progression-free survival was derived based on scan/assessment dates, not visit dates.</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.6" upper_limit="5.5"/>
                    <measurement group_id="O2" value="5.5" lower_limit="3.8" upper_limit="7.1"/>
                    <measurement group_id="O3" value="4.2" lower_limit="3.9" upper_limit="5.6"/>
                    <measurement group_id="O4" value="12.0" lower_limit="8.6" upper_limit="13.1"/>
                    <measurement group_id="O5" value="2.7" lower_limit="1.7" upper_limit="NA">non calculable</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">non calculable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (Median, 95% CI)</title>
        <description>Progression-free survival (PFS) was defined as the elapsed time from date of first dose of AZD1775 until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment.
Progression-free survival was derived based on scan/assessment dates, not visit dates.</description>
        <time_frame>Throughout the Study, Approximately 4 years</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (Median, 95% CI)</title>
          <description>Progression-free survival (PFS) was defined as the elapsed time from date of first dose of AZD1775 until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment.
Progression-free survival was derived based on scan/assessment dates, not visit dates.</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.3" upper_limit="5.5"/>
                    <measurement group_id="O2" value="5.5" lower_limit="3.7" upper_limit="7.4"/>
                    <measurement group_id="O3" value="4.2" lower_limit="2.8" upper_limit="8.9"/>
                    <measurement group_id="O4" value="12.0" lower_limit="2.7" upper_limit="NA">non calculable</measurement>
                    <measurement group_id="O5" value="2.7" lower_limit="0.5" upper_limit="NA">non calculable</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">non calculable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Median, 80% CI)</title>
        <description>Overall survival (OS) was defined as the elapsed time from the date of first dose of AZD1775 until death due to any cause. Any patient not known to have died at the time of the analysis was censored based on the last recorded date on which the patient was known to be alive.</description>
        <time_frame>Throughout the Study, Approximately 4 years</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Median, 80% CI)</title>
          <description>Overall survival (OS) was defined as the elapsed time from the date of first dose of AZD1775 until death due to any cause. Any patient not known to have died at the time of the analysis was censored based on the last recorded date on which the patient was known to be alive.</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="6.7" upper_limit="NA">non calculable</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="15.6" upper_limit="NA">Non calculable</measurement>
                    <measurement group_id="O3" value="8.9" lower_limit="8.0" upper_limit="NA">non calculable</measurement>
                    <measurement group_id="O4" value="19.2" lower_limit="12.4" upper_limit="19.2"/>
                    <measurement group_id="O5" value="3.8" lower_limit="2.0" upper_limit="6.2"/>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">non calculable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Median, 95% CI)</title>
        <description>Overall survival (OS) was defined as the elapsed time from the date of first dose of AZD1775 until death due to any cause. Any patient not known to have died at the time of the analysis was censored based on the last recorded date on which the patient was known to be alive.</description>
        <time_frame>Throughout the Study, Approximately 4 years</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Median, 95% CI)</title>
          <description>Overall survival (OS) was defined as the elapsed time from the date of first dose of AZD1775 until death due to any cause. Any patient not known to have died at the time of the analysis was censored based on the last recorded date on which the patient was known to be alive.</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="2.2" upper_limit="NA">non calculable</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="11.6" upper_limit="NA">non calculable</measurement>
                    <measurement group_id="O3" value="8.9" lower_limit="8.0" upper_limit="NA">non calculable</measurement>
                    <measurement group_id="O4" value="19.2" lower_limit="12.4" upper_limit="19.2"/>
                    <measurement group_id="O5" value="6.2" lower_limit="2.0" upper_limit="NA">non calculable</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">non calculable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gynecologic Cancer Intergroup (GCIG) CA-125 Response</title>
        <description>The GCIG CA-125 response is defined as the proportion of patients achieving a 50% reduction in CA-125 levels from baseline, if baseline level is â‰¥2 x the upper limit of normal (ULN) within 2 weeks prior to starting treatment. Response must be confirmed and maintained for at least 28 days.</description>
        <time_frame>Throughout the study, approximately 4 years</time_frame>
        <population>The CA-125 analysis set was comprised of all dosed patients with pre-treatment serum sample showing CA-125 â‰¥ 2 x ULN within 2 weeks before starting treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Gynecologic Cancer Intergroup (GCIG) CA-125 Response</title>
          <description>The GCIG CA-125 response is defined as the proportion of patients achieving a 50% reduction in CA-125 levels from baseline, if baseline level is â‰¥2 x the upper limit of normal (ULN) within 2 weeks prior to starting treatment. Response must be confirmed and maintained for at least 28 days.</description>
          <population>The CA-125 analysis set was comprised of all dosed patients with pre-treatment serum sample showing CA-125 â‰¥ 2 x ULN within 2 weeks before starting treatment.</population>
          <units>Percent</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="4.6" upper_limit="60.0"/>
                    <measurement group_id="O2" value="53.6" lower_limit="36.6" upper_limit="69.9"/>
                    <measurement group_id="O3" value="26.7" lower_limit="9.7" upper_limit="51.1"/>
                    <measurement group_id="O4" value="63.6" lower_limit="35.0" upper_limit="86.5"/>
                    <measurement group_id="O5" value="25.0" lower_limit="1.3" upper_limit="75.1"/>
                    <measurement group_id="O6" value="25.0" lower_limit="1.3" upper_limit="75.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) by Maximum CTCAE Grade.</title>
        <description>The number of patients experiencing at least one treatment-related adverse event (TEAE) by maximum CTCAE grade.
Severity Grade 1 = Mild; Severity Grade 2 = Moderate; Severity Grade 3 = Severe; Severity Grade 4 = Life Threatening; Severity Grade 5 = Fatal</description>
        <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) by Maximum CTCAE Grade.</title>
          <description>The number of patients experiencing at least one treatment-related adverse event (TEAE) by maximum CTCAE grade.
Severity Grade 1 = Mild; Severity Grade 2 = Moderate; Severity Grade 3 = Severe; Severity Grade 4 = Life Threatening; Severity Grade 5 = Fatal</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) Related to Adavosertib by Maximum CTCAE Grade</title>
        <description>The number and proportion of patients experiencing at least one treatment-related adverse event (TEAE) related to adavosertib by maximum CTCAE grade
Severity Grade 1 = Mild; Severity Grade 2 = Moderate; Severity Grade 3 = Severe; Severity Grade 4 = Life Threatening; Severity Grade 5 = Fatal</description>
        <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) Related to Adavosertib by Maximum CTCAE Grade</title>
          <description>The number and proportion of patients experiencing at least one treatment-related adverse event (TEAE) related to adavosertib by maximum CTCAE grade
Severity Grade 1 = Mild; Severity Grade 2 = Moderate; Severity Grade 3 = Severe; Severity Grade 4 = Life Threatening; Severity Grade 5 = Fatal</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) Related to Chemotherapy by Maximum CTCAE Grade</title>
        <description>The number of patients experiencing at least one treatment-related adverse event (TEAE) related to chemotherapy by maximum CTCAE grade.
Severity Grade 1 = Mild; Severity Grade 2 = Moderate; Severity Grade 3 = Severe; Severity Grade 4 = Life Threatening; Severity Grade 5 = Fatal</description>
        <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) Related to Chemotherapy by Maximum CTCAE Grade</title>
          <description>The number of patients experiencing at least one treatment-related adverse event (TEAE) related to chemotherapy by maximum CTCAE grade.
Severity Grade 1 = Mild; Severity Grade 2 = Moderate; Severity Grade 3 = Severe; Severity Grade 4 = Life Threatening; Severity Grade 5 = Fatal</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with â‰¥1 TEAE of max Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>The number of patients experiencing at least one serious adverse event (SAE).</description>
        <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>The number of patients experiencing at least one serious adverse event (SAE).</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pts. with â‰¥ one serious TEAE related to AZD1775.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pts. with â‰¥ one serious TEAE related to Chemo.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events Leading to Death</title>
        <description>The number of patients experiencing at least one serious adverse event (SAE) leading to death.</description>
        <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events Leading to Death</title>
          <description>The number of patients experiencing at least one serious adverse event (SAE) leading to death.</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No. with STEAE related to AZD1775 leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. with STEAE related to chemo leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-Related Adverse Events Related to Adavosertib Leading to Treatment Discontinuation</title>
        <description>The number of patients experiencing at least one treatment-related adverse event related to adavosertib leading to treatment discontinuation.</description>
        <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Related Adverse Events Related to Adavosertib Leading to Treatment Discontinuation</title>
          <description>The number of patients experiencing at least one treatment-related adverse event related to adavosertib leading to treatment discontinuation.</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-Related Adverse Events Related to Adavosertib Leading to Dose Reduction</title>
        <description>The number of patients experiencing at least one treatment-related adverse event related to adavosertib leading to dose reduction.</description>
        <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Related Adverse Events Related to Adavosertib Leading to Dose Reduction</title>
          <description>The number of patients experiencing at least one treatment-related adverse event related to adavosertib leading to dose reduction.</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-Related Adverse Events Related to Adavosertib Leading to Treatment Interruption</title>
        <description>The number of patients experiencing at least one treatment-related adverse event related to adavosertib leading to treatment interruption.</description>
        <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Related Adverse Events Related to Adavosertib Leading to Treatment Interruption</title>
          <description>The number of patients experiencing at least one treatment-related adverse event related to adavosertib leading to treatment interruption.</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-Related Adverse Events Related to Chemotherapy Leading to Treatment Discontinuation</title>
        <description>The number of patients experiencing at least one treatment-related adverse event related to chemotherapy leading to treatment discontinuation.</description>
        <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Related Adverse Events Related to Chemotherapy Leading to Treatment Discontinuation</title>
          <description>The number of patients experiencing at least one treatment-related adverse event related to chemotherapy leading to treatment discontinuation.</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-Related Adverse Events Related to Chemotherapy Leading to Dose Reduction</title>
        <description>The number of patients experiencing at least one treatment-related adverse event related to chemotherapy leading to dose reduction.</description>
        <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Related Adverse Events Related to Chemotherapy Leading to Dose Reduction</title>
          <description>The number of patients experiencing at least one treatment-related adverse event related to chemotherapy leading to dose reduction.</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-Related Adverse Events Related to Chemotherapy Leading to Treatment Interruption</title>
        <description>The number of patients experiencing at least one treatment-related adverse event related to chemotherapy leading to treatment interruption.</description>
        <time_frame>Throughout the duration of the study (up to 19 months)</time_frame>
        <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C2</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
          <group group_id="O5">
            <title>Arm D-175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O6">
            <title>Arm D-225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Related Adverse Events Related to Chemotherapy Leading to Treatment Interruption</title>
          <description>The number of patients experiencing at least one treatment-related adverse event related to chemotherapy leading to treatment interruption.</description>
          <population>This analysis was conducted on the Full Analysis Set, comprised of all patients who received at least dose of study treatment (n = 94).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Dose Adavosertib Cmax</title>
        <description>Maximum plasma concentration of adavosertib after a single oral dose (Cycle 1 Day 1) in combination with IV infusion of commonly used chemotherapy agents, including gemcitabine, paclitaxel, and carboplatin.</description>
        <time_frame>Pre-dose, 0.5 hr, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr</time_frame>
        <population>The PK Analysis Set included all dosed patients who had at least one measurable plasma concentration collected post-dose which was obtained without any protocol deviation, violation, or other event which may have significantly affected the pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A 800 mg/mÂ² Gemcitabine</title>
            <description>Adavosertib175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm A 1000 mg/mÂ² Gemcitabine</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 1000 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Dose Adavosertib Cmax</title>
          <description>Maximum plasma concentration of adavosertib after a single oral dose (Cycle 1 Day 1) in combination with IV infusion of commonly used chemotherapy agents, including gemcitabine, paclitaxel, and carboplatin.</description>
          <population>The PK Analysis Set included all dosed patients who had at least one measurable plasma concentration collected post-dose which was obtained without any protocol deviation, violation, or other event which may have significantly affected the pharmacokinetics.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477.4" spread="3.776"/>
                    <measurement group_id="O2" value="571.1" spread="29.79"/>
                    <measurement group_id="O3" value="533.8" spread="37.29"/>
                    <measurement group_id="O4" value="556.6" spread="56.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Dose Adavosertib Cmax</title>
        <description>Maximum plasma concentration of adavosertib after a multiple oral doses (Cycle 1 Day 3) in combination with IV infusion of 40 mg/mÂ² pegylated liposomal doxorubicin.</description>
        <time_frame>Pre-dose, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr</time_frame>
        <population>The PK Analysis Set included all dosed patients who had at least one measurable plasma concentration collected post-dose which was obtained without any protocol deviation, violation, or other event which may have significantly affected the pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm D 175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm D 225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Adavosertib Cmax</title>
          <description>Maximum plasma concentration of adavosertib after a multiple oral doses (Cycle 1 Day 3) in combination with IV infusion of 40 mg/mÂ² pegylated liposomal doxorubicin.</description>
          <population>The PK Analysis Set included all dosed patients who had at least one measurable plasma concentration collected post-dose which was obtained without any protocol deviation, violation, or other event which may have significantly affected the pharmacokinetics.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4135" spread="65.8"/>
                    <measurement group_id="O2" value="23530" spread="30.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Dose Adavosertib Tmax</title>
        <description>The time to reach maximum plasma concentration of adavosertib after a single oral dose (Cycle 1 Day 1) in combination with IV infusion of commonly used chemotherapy agents, including gemcitabine, paclitaxel, and carboplatin.</description>
        <time_frame>Pre-dose, 0.5 hr, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr</time_frame>
        <population>The PK Analysis Set included all dosed patients who had at least one measurable plasma concentration collected post-dose which was obtained without any protocol deviation, violation, or other event which may have significantly affected the pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A 800 mg/mÂ² Gemcitabine</title>
            <description>Adavosertib175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm A 1000 mg/mÂ² Gemcitabine</title>
            <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles.
Gemcitabine 1000 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Arm B</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
          </group>
          <group group_id="O4">
            <title>Arm C</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Single Dose Adavosertib Tmax</title>
          <description>The time to reach maximum plasma concentration of adavosertib after a single oral dose (Cycle 1 Day 1) in combination with IV infusion of commonly used chemotherapy agents, including gemcitabine, paclitaxel, and carboplatin.</description>
          <population>The PK Analysis Set included all dosed patients who had at least one measurable plasma concentration collected post-dose which was obtained without any protocol deviation, violation, or other event which may have significantly affected the pharmacokinetics.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.90" upper_limit="2.08"/>
                    <measurement group_id="O2" value="2.02" lower_limit="0.50" upper_limit="4.05"/>
                    <measurement group_id="O3" value="4.08" lower_limit="1.97" upper_limit="8.00"/>
                    <measurement group_id="O4" value="3.15" lower_limit="1.75" upper_limit="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Dose Adavosertib Tmax</title>
        <description>The time to reach maximum plasma concentration of adavosertib after multiple oral doses (Cycle 1 Day 3) in combination with IV infusion of 40 mg/mÂ² pegylated liposomal doxorubicin.</description>
        <time_frame>Pre-dose, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr</time_frame>
        <population>The PK Analysis Set included all dosed patients who had at least one measurable plasma concentration collected post-dose which was obtained without any protocol deviation, violation, or other event which may have significantly affected the pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm D 175 mg</title>
            <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm D 225 mg</title>
            <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Adavosertib Tmax</title>
          <description>The time to reach maximum plasma concentration of adavosertib after multiple oral doses (Cycle 1 Day 3) in combination with IV infusion of 40 mg/mÂ² pegylated liposomal doxorubicin.</description>
          <population>The PK Analysis Set included all dosed patients who had at least one measurable plasma concentration collected post-dose which was obtained without any protocol deviation, violation, or other event which may have significantly affected the pharmacokinetics.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" lower_limit="1.67" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.88" lower_limit="1.87" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study, approximately 19 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A</title>
          <description>Adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. Gemcitabine 800 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
        </group>
        <group group_id="E2">
          <title>Arm B</title>
          <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 28 day cycles. Paclitaxel 80 mg/mÂ² IV on Days 1, 8, and 15 of 28 day cycles.</description>
        </group>
        <group group_id="E3">
          <title>Arm C</title>
          <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 21 day cycles.
Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
        </group>
        <group group_id="E4">
          <title>Arm C2</title>
          <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3, 8-10, and 15-17 of 21 day cycles. Carboplatin AUC 5 IV on Day 1 of 21 day cycles.</description>
        </group>
        <group group_id="E5">
          <title>Arm D-175 mg</title>
          <description>Adavosertib 175 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
        </group>
        <group group_id="E6">
          <title>Arm D-225 mg</title>
          <description>Adavosertib 225 mg orally BID (5 doses over 3 days) on Days 1-3 of 28 day cycles.
Pegylated liposomal doxorubicin 40 mg/mÂ² IV on Day 1 of 28 day cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Kidney Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Liver Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenic Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paraspinal Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vascular Device Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Stoma Complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion Related Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="82" subjects_affected="24" subjects_at_risk="38"/>
                <counts group_id="E3" events="45" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E4" events="48" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" events="25" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E3" events="14" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" events="51" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="8" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E3" events="33" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E4" events="90" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="67" subjects_affected="31" subjects_at_risk="38"/>
                <counts group_id="E3" events="33" subjects_affected="16" subjects_at_risk="23"/>
                <counts group_id="E4" events="11" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="9" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Reflux Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" events="49" subjects_affected="23" subjects_at_risk="38"/>
                <counts group_id="E3" events="38" subjects_affected="19" subjects_at_risk="23"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" events="7" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" events="41" subjects_affected="19" subjects_at_risk="38"/>
                <counts group_id="E3" events="24" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E4" events="9" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="33" subjects_affected="23" subjects_at_risk="38"/>
                <counts group_id="E3" events="30" subjects_affected="17" subjects_at_risk="23"/>
                <counts group_id="E4" events="11" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oedema, Peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="11" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" events="64" subjects_affected="13" subjects_at_risk="38"/>
                <counts group_id="E3" events="17" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E3" events="19" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="64" subjects_affected="11" subjects_at_risk="38"/>
                <counts group_id="E3" events="17" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="12" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="18" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E3" events="8" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pejvack Motlagh, MD</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+44 (0) 7384 799 850</phone>
      <email>pejvack.motlagh@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

